These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9285479)

  • 1. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
    Ballard C; Massey H; Lamb H; Morris C
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):273-4. PubMed ID: 9285479
    [No Abstract]   [Full Text] [Related]  

  • 2. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
    Holmes C; Levy R; McLoughlin DM; Powell JF; Lovestone S
    J Neurol Neurosurg Psychiatry; 1996 Dec; 61(6):580-3. PubMed ID: 8971103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.
    Murphy GM; Taylor J; Kraemer HC; Yesavage J; Tinklenberg JR
    Am J Psychiatry; 1997 May; 154(5):603-8. PubMed ID: 9137113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E and cognitive decline in Alzheimer's disease.
    Plassman BL; Breitner JC
    Neurology; 1996 Aug; 47(2):317-20. PubMed ID: 8756999
    [No Abstract]   [Full Text] [Related]  

  • 5. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
    Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
    Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism in the cholesterol 24S-hydroxylase gene (CYP46A1) associated with the APOEpsilon3 allele increases the risk of Alzheimer's disease and of mild cognitive impairment progressing to Alzheimer's disease.
    Fernández Del Pozo V; Alvarez Alvarez M; Fernández Martínez M; Galdós Alcelay L; Gómez Busto F; Peña JA; Alfonso-Sánchez MA; Zarranz Imirizaldu JJ; de Pancorbo MM
    Dement Geriatr Cogn Disord; 2006; 21(2):81-7. PubMed ID: 16340204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein e4 allele and cognitive decline. May be less relevant.
    Frisoni GB; Bianchetti A; Franceschini G; Govoni S; Trabucchi M
    BMJ; 1995 Feb; 310(6975):330-1. PubMed ID: 7755725
    [No Abstract]   [Full Text] [Related]  

  • 8. Apolipoprotein E-epsilon 4 allele doses in late-onset Alzheimer's disease.
    Lucotte G; Turpin JC; Landais P
    Ann Neurol; 1994 Oct; 36(4):681-2. PubMed ID: 7944308
    [No Abstract]   [Full Text] [Related]  

  • 9. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
    Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
    Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the associations between Alzheimer's disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium?
    Tsuda T; Lopez R; Rogaeva EA; Freedman M; Rogaev E; Drachman D; Pollen D; Haines J; Liang Y; McLachlan DR
    Ann Neurol; 1994 Jul; 36(1):97-100. PubMed ID: 8024269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease.
    Harwood DG; Barker WW; Ownby RL; St George-Hyslop P; Duara R
    Am J Geriatr Psychiatry; 1999; 7(2):119-23. PubMed ID: 10322238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele predicted accelerated rate of cognitive decline in Alzheimer's disease.
    Burke D
    West J Med; 1999 Jul; 171(1):23. PubMed ID: 10483340
    [No Abstract]   [Full Text] [Related]  

  • 13. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apo-E genotype and verbal deficits in Alzheimer's disease.
    Rasmusson DX; Dal Forno G; Brandt J; Warren AC; Troncoso J; Lyketsos C
    J Neuropsychiatry Clin Neurosci; 1996; 8(3):335-7. PubMed ID: 8854306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer's disease.
    Lucotte G; Visvikis S; Leininger-Müler B; David F; Berriche S; Réveilleau S; Couderc R; Babron MC; Aguillon D; Siest G
    Am J Med Genet; 1994 Sep; 54(3):286-8. PubMed ID: 7810590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease.
    Lucotte G; Aouizérate A; Gérard N; Turpin JC; Landais P
    Am J Med Genet; 1995 Dec; 60(6):566-9. PubMed ID: 8825898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease.
    Matsui T; Higuchi M; Okamura N; Arai H; Sasaki H
    Neurology; 1999 Dec; 53(9):2208-9. PubMed ID: 10599813
    [No Abstract]   [Full Text] [Related]  

  • 18. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.
    Smits LL; Pijnenburg YA; Koedam EL; van der Vlies AE; Reuling IE; Koene T; Teunissen CE; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2012; 30(1):101-8. PubMed ID: 22366769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
    Martins CA; Oulhaj A; de Jager CA; Williams JH
    Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.